Challenges to developing proteomic-based breast cancer diagnostics.

Over the past decade, multiple genetic and histological approaches have accelerated development of new breast cancer diagnostics and treatment paradigms. Multiple distinct genetic subtypes of breast cancers have been defined, and this has progressively led toward more personalized medicine in regard to treatment options. There still remains a deficiency in the development of molecular diagnostic assays that can be used for breast cancer detection and pretherapy clinical decisions. In particular, the type of cancer-specific biomarker typified by a serum or tissue-derived protein. Progress in this regard has been minimal, especially in comparison to the rapid advancements in genetic and histological assays for breast cancers. In this review, some potential reasons for this large gap in developing protein biomarkers will be discussed, as well as new strategies for improving these approaches. Improvements in the study design of protein biomarker discovery strategies in relation to the genetic subtypes and histology of breast cancers is also emphasized. The current successes in use of genetic and histological assays for breast cancer diagnostics are summarized, and in that context, the current limitations of the types of breast cancer-related clinical samples available for protein biomarker assay development are discussed. Based on these limitations, research strategies emphasizing identification of glycoprotein biomarkers in blood and MALDI mass spectrometry imaging of tissues are described.

[1]  B. Haab,et al.  Analysis of glycans on serum proteins using antibody microarrays. , 2009, Methods in molecular biology.

[2]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[3]  M. Mayo,et al.  Breast-tissue sampling for risk assessment and prevention. , 2005, Endocrine-related cancer.

[4]  W. Hancock,et al.  Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap--Fourier transform mass spectrometry. , 2006, Glycobiology.

[5]  André M Deelder,et al.  Glycoproteomics based on tandem mass spectrometry of glycopeptides. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  D. Chan,et al.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.

[7]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[8]  J. Hirabayashi.  Lectin-based structural glycomics: Glycoproteomics and glycan profiling , 2004, Glycoconjugate Journal.

[9]  Soonmyung Paik,et al.  Gene-expression-based prognostic assays for breast cancer , 2010, Nature Reviews Clinical Oncology.

[10]  Maria P. Pavlou,et al.  Nipple aspirate fluid proteome of healthy females and patients with breast cancer. , 2010, Clinical chemistry.

[11]  Christoph H Borchers,et al.  Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma* , 2009, Molecular & Cellular Proteomics.

[12]  A. Kuno,et al.  Focused Differential Glycan Analysis with the Platform Antibody-assisted Lectin Profiling for Glycan-related Biomarker Verification*S , 2009, Molecular & Cellular Proteomics.

[13]  Jacob J. Kennedy,et al.  The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. , 2010, Journal of chromatography. A.

[14]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[15]  Carole Mathelin,et al.  Serum biomarkers for detection of breast cancers: a prospective study , 2006, Breast Cancer Research and Treatment.

[16]  T. Nielsen,et al.  Biomarkers for Basal-like Breast Cancer , 2010, Cancers.

[17]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[19]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[20]  Mary Ann Comunale,et al.  Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. , 2009, Journal of proteome research.

[21]  Richard M. Caprioli,et al.  MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. , 2008, Analytical chemistry.

[22]  C. Couldrey,et al.  Metastases: the glycan connection , 2000, Breast Cancer Research.

[23]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[24]  S. Love,et al.  The intraductal approach to the breast: raison d'être , 2006, Breast Cancer Research.

[25]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[26]  Mary Ann Comunale,et al.  Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma , 2010, PloS one.

[27]  Kristina Schwamborn,et al.  Molecular imaging by mass spectrometry — looking beyond classical histology , 2010, Nature Reviews Cancer.

[28]  W. Hauck,et al.  Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 women and literature review , 2005, Breast Cancer Research and Treatment.

[29]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[30]  Richard M Caprioli,et al.  A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer* , 2006, Molecular & Cellular Proteomics.

[31]  R. Caprioli,et al.  Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation , 2010, Clinical Cancer Research.

[32]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[33]  Florian Gnad,et al.  Precision Mapping of an In Vivo N-Glycoproteome Reveals Rigid Topological and Sequence Constraints , 2010, Cell.

[34]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[35]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[36]  Ljiljana Paša-Tolić,et al.  Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer*S⃞ , 2009, Molecular & Cellular Proteomics.

[37]  O. J. Semmes,et al.  Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers* , 2006, Molecular & Cellular Proteomics.

[38]  M. Duffy,et al.  Serum tumor markers in breast cancer: are they of clinical value? , 2006, Clinical chemistry.

[39]  M. Dwek,et al.  Proteome and glycosylation mapping identifies post‐translational modifications associated with aggressive breast cancer , 2001, Proteomics.

[40]  S. Obenauer,et al.  Applications and literature review of the BI-RADS classification , 2005, European Radiology.

[41]  Mitsuhiro Tada,et al.  BlotGlycoABC™, an Integrated Glycoblotting Technique for Rapid and Large Scale Clinical Glycomics *S , 2008, Molecular & Cellular Proteomics.

[42]  Naoyuki Taniguchi,et al.  Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. , 2007, Glycobiology.

[43]  Ronald J Moore,et al.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. , 2005, Journal of proteome research.

[44]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[45]  Robert Camp,et al.  β1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma , 2005, Clinical Cancer Research.

[46]  M. Duffy,et al.  Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations , 2005, Tumor Biology.

[47]  Bingcheng Lin,et al.  Integrated lectin affinity microfluidic chip for glycoform separation. , 2004, Analytical chemistry.

[48]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[49]  M. Mainiero,et al.  BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. , 2006, Radiology.

[50]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Kerby Shedden,et al.  Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. , 2007, Journal of proteome research.

[52]  J. Tabet,et al.  Improvements of TArgeted multiplex mass spectrometry IMaging , 2008, Proteomics.

[53]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[54]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Jeffrey S. Morris,et al.  The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. , 2005, Briefings in functional genomics & proteomics.

[56]  D. Rimm,et al.  Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer , 2005, Breast Cancer Research.

[57]  O. John Semmes,et al.  SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers , 2004, Disease markers.

[58]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[59]  C. Laronga,et al.  Proteomic approach to breast cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[60]  L. Cazares,et al.  Serum biomarkers to differentiate benign and malignant mammographic lesions. , 2007, Journal of the American College of Surgeons.

[61]  K. Murayama,et al.  Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects , 2008, International journal of cancer.

[62]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[63]  M. García-Closas,et al.  CEBP Focus: Biomarkers and Biospecimens , 2010 .

[64]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[65]  Soonmyung Paik,et al.  Gene expression profiling of breast cancer: a new tumor marker. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M. Dwek,et al.  Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[67]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[68]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[69]  K. Aoki,et al.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma. , 2008, Journal of proteome research.

[70]  Lisa H Cazares,et al.  Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.

[71]  G. Acs,et al.  Gene expression profiling in breast cancer. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[72]  Ruedi Aebersold,et al.  Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.